Document Classification

Section Type: RESULTS

Text: In the base-case analysis, the incremental cost-effectiveness ratio was (1) JPY 12 million (110, 000) per quality-adjusted life year (QALY) gained and JPY 8. 9 million (81, 000) per life-year gained (LYG) for all HER2-positive populations, (2) JPY 9. 1 million (83, 000) per QALY gained and JPY 6. 6 million (60, 000) per LYG for the IHC 2 + / FISH + or IHC 3 + population, and (3) JPY 6. 1 million (55, 000) per QALY gained and JPY 4. 3 million (39, 000) per LYG for the IHC 3 + population.